Cargando…
Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.
Acquired resistance to anthracyclines is characterised by a lower sensitivity to these agents, associated with impaired accumulation of drug. We have examined the ability of aclacinomycin A (ACM) associated with doxorubicin (DOX), to increase intranuclear DOX concentrations and, consequently, to enh...
Autores principales: | Millot, J. M., Rasoanaivo, T. D., Morjani, H., Manfait, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247305/ https://www.ncbi.nlm.nih.gov/pubmed/2803945 |
Ejemplares similares
-
Genomic amplification of chromosome 7 in the Doxorubicin resistant K562 cell line
por: Ibrahim, Sara.M, et al.
Publicado: (2018) -
Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562
por: Sargent, J M, et al.
Publicado: (2001) -
Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation
por: Lee, Yueh-Lun, et al.
Publicado: (2013) -
Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells
por: KANG, QINGWEI, et al.
Publicado: (2015) -
Rethinking Biosynthesis of Aclacinomycin A
por: Xu, Ziling, et al.
Publicado: (2023)